Pablo G. Legorreta - Nov 5, 2025 Form 4 Insider Report for Royalty Pharma plc (RPRX)

Role
CEO, Chairman of the Board, Director
Signature
/s/ Sean Weisberg, as Attorney-in-Fact for Pablo G. Legorreta
Stock symbol
RPRX
Transactions as of
Nov 5, 2025
Transactions value $
$0
Form type
4
Date filed
11/7/2025, 04:19 PM
Previous filing
Aug 8, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Legorreta Pablo G. CEO, Chairman of the Board, Director C/O ROYALTY PHARMA PLC, 110 E. 59TH STREET, NEW YORK /s/ Sean Weisberg, as Attorney-in-Fact for Pablo G. Legorreta 2025-11-07 0001507678

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RPRX Class A Ordinary Shares Award $0 +36.6K +4.04% $0.00 941K Nov 5, 2025 Direct F1
holding RPRX Class A Ordinary Shares 1.04M Nov 5, 2025 By Legorreta Children 2002 Trust
holding RPRX Class A Ordinary Shares 902K Nov 5, 2025 By GST-Exempt Legorreta 2012 Family Trust
holding RPRX Class A Ordinary Shares 600K Nov 5, 2025 By Legorreta 2023 SR Trust
holding RPRX Class A Ordinary Shares 460K Nov 5, 2025 By Legorreta Investments LLC
holding RPRX Class A Ordinary Shares 292K Nov 5, 2025 By Tata MC 35 Ltd.
holding RPRX Class A Ordinary Shares 123K Nov 5, 2025 By IRRA
holding RPRX Class A Ordinary Shares 119K Nov 5, 2025 By SEP/IRA
holding RPRX Class A Ordinary Shares 41.3K Nov 5, 2025 By GST-Exempt Legorreta 2020 Family Trust
holding RPRX Class A Ordinary Shares 10K Nov 5, 2025 By Son
holding RPRX Class A Ordinary Shares 10K Nov 5, 2025 By Daughter
holding RPRX Class A Ordinary Shares 6.93K Nov 5, 2025 By Spouse
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.